Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

1 Mar 2024

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation and Thrombosis Mechanisms
Share to Hemophilia Treatment and Research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38437857
DOI: 10.1016/s2352-3026(24)00006-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trialPMID 38437857Read ↗

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia BSemantic proximity Read ↗

Etranacogene dezaparvovec for hemophilia B gene therapySemantic proximity Read ↗

Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia ASemantic proximity Read ↗

The Arrival of Gene Therapy for Patients with Hemophilia ASemantic proximity Read ↗

Roctavian gene therapy for hemophilia ASemantic proximity Read ↗

Gene-based therapies for hemophiliaSemantic proximity Read ↗

Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta studySemantic proximity Read ↗

Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trialSemantic proximity Read ↗

Gene therapy in hemophilia: the dawn of a new eraSemantic proximity Read ↗

Advances in gene therapy for hemophilia: basis, current status, and future perspectivesSemantic proximity Read ↗

Emerging therapies for hemophilia: controversies and unanswered questionsSemantic proximity Read ↗

Advances in Gene Therapy for HemophiliaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.